Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population. METHODS: A total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis. RESULTS: The pharmacokinetics of durvalumab was adequately described by a two-compartment model with first-order elimination. A decrease in durvalumab clearance over time was mainly explained by incorporation of time-dependent changes in albumin (in all patients) and immunoglobulin G (in patients with multiple myeloma) into the model. For multiple myeloma, patients with immunoglobulin G ≥ 20 g/L showed a 30% lower area under the concentration-time curve at cycle 1 compared with patients with immunoglobulin G
In this study, we show that LOC389641 is involved in PTC, which suggests that it may be a target for TC therapies. PMID: 32940082 [PubMed - in process]
Conclusion: STAT6 may act as a prognostic biomarker and provide useful information for immunotherapy in thyroid carcinoma. PMID: 32940081 [PubMed - in process]
Conclusion: The results suggest that the regulation of miR-505/HNRNPM may be a novel strategy to improve the targeted therapy of HCC. PMID: 32940078 [PubMed - in process]
Authors: Moll SA, Wiertz IA, Vorselaars AD, Zanen P, Ruven HJ, van Moorsel CH, Grutters JC Abstract Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital capacity and diffusing capacity of the lung for carbon monoxid...
Biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer. Biomark Med. 2020 Jul;14(11):929-932 Authors: Fuschillo S, Battiloro C, Rocco D, D Gravara L, Motta A, Maniscalco M PMID: 32940076 [PubMed - in process]
Conclusion: Metabolite biomarker candidates for PC are useful for detecting high-risk IPMN, which can progress to PC. PMID: 32940075 [PubMed - in process]
Conclusion: This study indicated that approximately a third of the CRC patients are diagnosed with EMAST, hereupon EMAST as a prognostic and predictive biomarker should be more studied clinically. PMID: 32940074 [PubMed - in process]
This article aims to review current advances in revealing relationship between tumors and abnormal N-glycosylation and discuss leading-edge applications of N-glycosylation in developing novel tumor biomarkers. PMID: 32940073 [PubMed - in process]
CONCLUSIONS: Despite the relatively small sample size of the South Australian cohort, clinical and serological characteristics correspond closely with international descriptions. PMID: 32940213 [PubMed - as supplied by publisher]
Positive histopathologic assessment in salivary glands shows little impact on clinical features of established primary Sjögren's syndrome in a Korean population. Clin Exp Rheumatol. 2020 Sep 08; Authors: Park Y, Lee J, Koh JH, Choe JY, Sung YK, Lee SS, Shim SC, Kim JM, Kwon SR, Park SH, Kwok SK Abstract OBJECTIVES: The presence and severity of focal lymphocytic sialadenitis in minor salivary glands is a pathognomonic feature in primary Sjögren's syndrome (pSS). However, it has not been determined whether performing minor salivary gland biopsy (MSGB) in a setting of serologically and clinicall...